Tesaro bulls cheer takeover talk

19 November 2018

According to media, US drugmaker and PARP inhibitor specialist Tesaro (Nasdaq: TSRO) is considering a sale. Shares in the firm are up over a quarter since the news broke.

The report in Bloomberg quotes unnamed sources as saying that the firm “is working with financial advisers after receiving takeover interest,” but that no decision had been made yet.

Even after the recent share price bump, the firm’s market capitalization is less than half what it was at the start of the year, as Tesaro has struggled with disappointing clinical results and confident competition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK